Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort

Rhea-AI Summary

Philips (NYSE: PHG) announced availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems on February 12, 2026. The coil received FDA 510(k) clearance and is designed to improve pediatric comfort with a soft, flexible, blanket-like form while enabling high-density, high-resolution imaging.

The device aims to reduce repeat scans and speed setup, improving technologist workflow; it is available in the United States now, with broader regional rollout planned.

Positive

• Received FDA 510(k) clearance for pediatric use
• Designed for compatibility with Philips 3.0T MRI systems
• Aims to reduce repeat exams and improve workflow efficiency

Negative

• Initial commercial availability limited to the United States only

News Market Reaction – PHG

-2.06%

1 alert

-2.06% News Effect

On the day this news was published, PHG declined 2.06%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Publication date: February 12, 2026 MRI field strength: 3.0T FDA pathway: 510(k) +5 more

8 metrics

Publication date February 12, 2026 Press release date for Snuggle pediatric MRI coil availability

MRI field strength 3.0T Snuggle pediatric body array coil compatibility with Philips MRI systems

FDA pathway 510(k) Snuggle coil recently cleared via U.S. FDA 510(k) process

Share price $32.07 Price before article, down 2.55% over prior 24 hours

52-week range $20.606–$33.435 Current price 55.63% above low and 4.08% below high

Market cap $31,296,718,890 Market capitalization prior to this product launch news

Daily volume 1,621,524 shares Trading volume vs 20-day average of 1,171,548 shares

Contact phone +1 416 270 6757 Media contact number provided in the release

Market Reality Check

Price: $26.45 Vol: Volume 1,621,524 is 38% a...

normal vol

$26.45 Last Close

Volume Volume 1,621,524 is 38% above the 20-day average of 1,171,548. normal

Technical Trading ~20% above the 200-day MA of 26.65, near the 52-week high and 55.63% above the 52-week low.

Peers on Argus

PHG was down 2.55% with mixed peer moves: ZBH up 5.22%, DXCM down 0.23%, PODD do...

PHG was down 2.55% with mixed peer moves: ZBH up 5.22%, DXCM down 0.23%, PODD down 0.38%, STE flat, SNN unchanged. This points to a stock-specific move rather than a broad medical devices trend.

Historical Context

5 past events · Latest: Feb 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Full-year 2025 results	Positive	+11.1%	Reported 2025 growth acceleration, margin expansion, cash flow and 2026–2028 targets.
Feb 10	CEO re-appointment plan	Positive	+11.1%	Proposed re-appointing CEO Roy Jakobs amid noted productivity savings and improved metrics.
Jan 29	Tech leadership award	Positive	+0.8%	Received Frost & Sullivan 2025 Global Enabling Technology Leadership recognition in digital pathology.
Jan 21	Innovation recognition	Positive	+2.5%	Named Clarivate Top 100 Global Innovator 2026 for 13th straight year with strong R&D focus.
Jan 14	Business separation	Positive	+1.6%	Completion of Emergency Care business sale and Heartstream launch under Philips brand license.

Pattern Detected

Recent Philips news events, mainly positive on growth, innovation, and portfolio changes, have generally coincided with positive 24-hour price reactions.

Recent Company History

Over recent weeks, Philips has reported multiple positive milestones. On Feb 10, 2026, it highlighted full-year 2025 growth acceleration, margin expansion, solid cash flow, and introduced 2026–2028 targets, alongside a proposal to re-appoint CEO Roy Jakobs, with both items seeing a 11.11% next-day gain. Earlier in January 2026, the company received a Frost & Sullivan technology leadership award, was named a Clarivate Top 100 Global Innovator, and completed the separation of its Emergency Care business into Heartstream, each accompanied by modestly positive price moves.

Market Pulse Summary

This announcement highlights a pediatric-focused expansion of Philips’ 3.0T MRI ecosystem via InkSpa...

Analysis

This announcement highlights a pediatric-focused expansion of Philips’ 3.0T MRI ecosystem via InkSpace Imaging’s Snuggle coil, recently cleared through the FDA’s 510(k) process. It reinforces ongoing themes from recent news: innovation recognition, portfolio refinement, and clinical workflow efficiency. Investors following Philips may watch for data on adoption in U.S. hospitals, regional rollout timing, and how such comfort- and efficiency-focused solutions complement the multi-year growth and margin ambitions shared for 2026–2028.

Key Terms

3.0t mri systems, pediatric body array coil, mri exams, high-density array, +4 more

8 terms

3.0t mri systems medical

"availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems"

3.0T MRI systems are magnetic resonance imaging machines that use a 3.0 tesla magnetic field—about 60,000 times the Earth's magnetic field—to create high-resolution pictures of the body's organs and tissues. They matter to investors because the stronger magnetic field can produce clearer images and faster scans, which hospitals and clinics value like a higher-resolution camera; that preference can boost sales, service contracts and pricing power for manufacturers and suppliers.

pediatric body array coil medical

"announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil"

A pediatric body array coil is a specialized piece of medical hardware used with MRI machines to capture detailed images of a child’s torso, designed to fit smaller bodies and reduce motion blur. For investors, these coils matter because they influence hospital buying decisions, scanning accuracy, patient throughput and safety, and therefore can affect revenue for imaging-equipment makers and the adoption rate of new MRI systems—think of it as a camera lens optimized for small subjects.

mri exams medical

"Young patients often find MRI exams challenging, and the Snuggle™ coil was created"

MRI exams are medical imaging scans that use strong magnets and radio waves to create detailed pictures of the inside of the body, like a camera that can see tissues, organs and injuries without surgery or X-rays. For investors, MRI volumes and technological advances matter because they drive revenue for hospitals, diagnostic centers and equipment makers, affect reimbursement and insurance trends, and signal demand for upgrades and maintenance — similar to how demand for new phones boosts phone makers and service providers.

high-density array technical

"The Snuggle coil’s high-density array and flexible design allow sharp, high-resolution images"

A high-density array is a compact laboratory tool that places thousands to millions of tiny test spots on a single surface so many biological or chemical measurements can be run at once, like turning a countertop into the equivalent of a large testing lab. For investors, it matters because that ability to test many samples or targets simultaneously can cut costs, speed product development, create scalable revenue streams, and build technical barriers that affect market competitiveness and regulatory scrutiny.

510(k) process regulatory

"Recently cleared through the U.S. Food and Drug Administration (FDA) 510(k) process"

A 510(k) process is the U.S. Food and Drug Administration’s review pathway for medical devices that shows a new device is as safe and effective as a similar, already‑sold device. It’s like proving a new tool works like an established one so it can be legally marketed without the longer, more rigorous approval route. Investors care because 510(k) clearance often means faster market access, lower regulatory cost and clearer revenue timing, while delays or denials add risk.

u.s. food and drug administration regulatory

"Recently cleared through the U.S. Food and Drug Administration (FDA) 510(k) process"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

pediatric medical

"Designed specifically for pediatric patients, the Snuggle coil has been optimized"

Relating to the medical care, products, or research specifically for infants, children, and adolescents. It matters to investors because treatments, devices, or drugs designed for this age group face different safety standards, testing requirements and market dynamics than adult products—think of it like tailoring clothing to fit a child rather than an adult, which changes design, approval hurdles and potential customer size, affecting regulatory risk and revenue prospects.

radiologists medical

"supporting radiologists, technologists, and families with safer, faster, and more effective MRI exams"

Radiologists are medical doctors who use imaging tools—such as X-rays, CT scans, MRIs and ultrasounds—to detect, diagnose and sometimes guide treatment of illnesses and injuries. Investors pay attention because radiologists drive demand for imaging equipment, software and hospital services, influence how quickly patients receive care, and affect reimbursement and adoption trends much like mechanics determine the demand for specialized tools in an auto shop.

AI-generated analysis. Not financial advice.

February 12, 2026

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality imaging for clinicians.

Young patients often find MRI exams challenging, and the Snuggle™ coil was created to make the experience more comfortable and less intimidating. Its light, blanket-like design and soft, flexible structure gently wrap around the patient.

The Snuggle coil’s high-density array and flexible design allow sharp, high-resolution images and more efficient exams across a range of pediatric anatomies. These advantages can reduce the need for additional imaging or follow-up procedures while helping technologists work more efficiently through easier handling, faster setup and shorter scan times, helping to improve throughput and reduce repeat exams.

“This collaboration combines Philips MRI leadership with InkSpace Imaging’s focus on pediatric design,” said Ioannis Panagiotelis, PhD, Business Leader, MR at Philips. “The Snuggle coil shows how thoughtful design can make MRI scans less stressful for children while giving clinicians the image quality and workflow efficiency they rely on.”

Recently cleared through the U.S. Food and Drug Administration (FDA) 510(k) process, InkSpace Imaging developed the Snuggle coil to provide a more child-friendly alternative to traditional rigid devices.

“Snuggle was designed and built by InkSpace Imaging to solve a very specific pediatric challenge: comfort and performance without tradeoffs,” said Dr. Peter Fischer, CEO, InkSpace Imaging. “By enabling compatibility with Philips 3.0T MRI systems, we can bring that child-centered design to more hospitals and help care teams get the scan right the first time.”

The Snuggle pediatric coil for Philips 3.0T MR systems is now available in the United States, with rollout to additional regions planned in the future. Philips and InkSpace Imaging continue to explore opportunities to expand comfort- and efficiency-focused coil technology, supporting radiologists, technologists, and families with safer, faster, and more effective MRI exams.

For further information, please contact:

Jayme Maniatis 
Philips Global External Relations  
Tel.: +1 416 270 6757 
E-mail: jayme.maniatis@philips.com 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Designed for Pediatric Comfort
• Flexible, High Density Coil Design
• Child Centered Innovation for 3.0T MRI

FAQ

What is the Philips PHG announcement about the Snuggle pediatric MRI coil on February 12, 2026?

Philips announced the availability of the InkSpace Imaging Snuggle pediatric coil for Philips 3.0T MRI systems with FDA 510(k) clearance. According to Philips, the coil is designed to improve child comfort while delivering high-density imaging and workflow benefits.

Is the Snuggle pediatric coil compatible with Philips 3.0T MR systems (PHG)?

Yes. The Snuggle coil is validated for use with Philips 3.0T MRI systems to ensure functional compatibility. According to Philips, InkSpace Imaging developed the device and verified performance on Philips 3.0T platforms.

How does the Snuggle coil claim to improve pediatric MRI exams for PHG systems?

The Snuggle coil uses a soft, flexible, blanket-like design to reduce patient stress and simplify setup. According to Philips, its high-density array supports sharp, high-resolution images while aiming to lower repeat scans and shorten exam times.

Where is the Snuggle pediatric coil for Philips 3.0T systems available now?

The coil is available in the United States immediately following FDA 510(k) clearance. According to Philips, a phased rollout to additional regions is planned for future availability.

What operational benefits does Philips say the Snuggle coil offers technologists?

Philips says the Snuggle coil enables easier handling, faster setup, and shorter scan times to help improve throughput. According to the company, these features can make exams more efficient and reduce the need for follow-up imaging.

Did Philips mention regulatory clearance for the Snuggle pediatric coil (PHG)?

Yes. The Snuggle pediatric coil cleared the U.S. Food and Drug Administration via the 510(k) process. According to Philips, this clearance supports the coil's commercial availability in the United States.